medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

The efficacy and safety of bamlanivimab treatment against COVID-19: A meta-analysis

Huai-rong Xiang [a], Bei He [a], Yun Li [a], Xuan Cheng [a], Qi-zhi Zhang [a], Wen-xing Peng [a, b] *

[a] Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China

[b] Institute of Clinical Pharmacy, Central South University, Changsha, Hunan 410011, China

*Corresponding author:

Phone: 0086-0731-88836044; Fax: 0086-0731-88836044

Email address: pwx.csu@csu.edu.cn

Full postal address: Department of Pharmacy, the Second Xiangya Hospital, Central South University, #139, Middle Renmin Road, Changsha, Hunan 410011, P.R. China

The full text words：4378

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Key points

Question: Can bamlanivimab treat COVID-19 patients? What are the factors that have great impact on the treatment outcome?

Findings: In this meta-analysis that retrieved 3 RCTs and 7 cohort studies and included 14461 adults, Bmlanivimab may help outpatients to prevent hospitalization or emergency department visit (RR 0.41 95%CI 0.29 to 0.58), reduce ICU admission (RR 0.47 95%CI 0.23 to 0.92) and mortality (RR 0.32 95%CI 0.13 to 0.77) from the disease.

Meaning: In COVID-19 pandemic, the use of bamlanivimab may be warranted. Combinations of two or more monoclonal antibody increase the effect.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

ABSTRACT

Background: Bamlanivimab is routinely used in the treatment of coronavirus disease 2019 (COVID-19) in worldwide. We performed a meta-analysis to investigate the efficacy and safety of bamlanivimab treatment in patients with COVID-19.

Methods: We searched articles from Web of Science, PubMed, Embase, the Cochrane Library and MedRxiv between 30 January 2020 and August 5, 2021. We selected randomized clinical trials (RCTs) and observational studies with a control group to assess the efficiency of bamlanivimab in treating patients with COVID-19.

Results: Our meta-analysis retrieved 3 RCTs and 7 cohort studies including 14461 patients. Bmlanivimab may help outpatients to prevent hospitalization or emergency department visit (RR 0.41 95%CI 0.29 to 0.58), reduce ICU admission (RR 0.47 95%CI 0.23 to 0.92) and mortality (RR 0.32 95%CI 0.13 to 0.77) from the disease. The combination of bamlanivimab and etesevimab may had a greater potential for positive treatment outcome.

Conclusion: Bamlanivimab has demonstrated clinical efficacy on mild or moderate ill patients with COVID-19 to prevent hospitalization, reduce severity and mortality from the disease. Combinations of two or more monoclonal antibody increase the effect. Well-designed clinical trials to identify the clinical and biochemical characteristics in COVID-19 patients' population that could benefit from bamlanivimab are warranted in the future.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Key words: bamlanivimab; COVID-19; Immunotherapy

INTRODUCTION

The Coronavirus disease 2019 (COVID-19) has become a major public hazard caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By August 2021, more than 203 million people have been reported to be infected with COVID-19, and 4 million people have died of it. Although the advent of vaccines has played a great role in epidemic prevention and control. In developing countries, the availability of vaccines has been slow[1]. Several of these COVID-19 therapeutic candidates are currently being studied in preclinical and clinical research stages around the world. Antibody based on viral spike protein (S protein) appears to be the main target of antibody development candidates[2].

Bamlanivimab, also known as LY-CoV555, is a lgG monoclonal antibody which mediate its effects by means of binding with the receptor-binding domain of SARS-CoV-2 to viral neutralization, complement activation and antibody-dependent cellular cytotoxicity[3, 4]. In November 2020, the Food and Drug Administration (FDA) authorized an emergency use authorization (EUA) for bamlanivimab, for treatment of mild to moderate COVID-19 in non-admitted patients at high risk for severe disease[5]. The benefits or harms of such monoclonal antibodies is limited. Thus, this meta-analysis, aims to summaries efficacy of bamlanivimab use in COVID-19 based on available evidence and find out the potential association between treatment with bamlanivimab and outcomes of COVID-19.

METHOD

This meta-analysis was described by the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA-P) statement[6]. and the guidelines of the Meta-analysis of Observational Studies in Epidemiology[7]. The protocol for

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

this study has been registered in the International Prospective Register of Systematic Reviews (PROSPERO, CRD42021272789).

Search strategy and study selection

Two experience researchers (Bei He and Xuan Cheng) based on The Peer Review of Electronic Search Strategies checklist[8] searched Web of Science, PubMed, Embase, the Cochrane Library, MedRxiv for clinical trials and observational studies. A combination of search terminologies ("Coronavirus Disease 2019" OR "COVID-19" OR "SARS-Cov-2" OR "2019-nCoV Diseases" OR "COVID 19 Virus Infection") AND ("LY-CoV555" OR "bamlanivimab"). Search was down on August 5, 2021 which was imposed restriction on the date between 1.1 2020 to 8.5 2021. No restriction on the geographical location or language of the studies. To be eligible for inclusion, studies must divide patients into treatment group using bamlanivimab and control group with no bamlanivimab. We also required that the studies reported data on any of the pre-determined outcomes. The studies aimed at preventing the occurrence of COVID-19 were excluded.

Data extraction

Two reviewers (Huai-rong Xiang, Yun Li) independently screened the titles and abstracts of the studies to retrieve articles and extracted data based on the inclusion and exclusion criteria. Any discrepancies will be resolved through discussion (with a third author, if necessary).

Each included article was thoroughly reviewed, the following data and information were extracted:

(1) The first author's name, publication date, country and study type.

(2) Patients' information

(2) Treatment plan (including dosage, timing of using bamlanivimab).

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(3) Outcome indicators.

Data was extracted and entered to a pre-defined and piloted Microsoft excel database.

Quality assessment

Two reviewers (Qi-zhi Zhang and Huai-rong Xiang) independently evaluated the quality of these literature. In case of any disagreement, the third reviewer (Yun Li) consulted for reconciling any difference of opinion. The version 2 Cochrane Risk of bias Assessment tool[9] was used to evaluate the methodological quality of the RCTs over five domains of selection, performance, blinding, completeness, and reporting. For each domain, risk of bias judgements is 'high', 'unclear' or 'low'. The Newcastle-Ottawa Scale (NOS)[10] was to evaluate the quality of the cohort studies which comprises three parts of patient selection, comparability, and research results. The total score is 9 which was divided into three categories: (a) high risk (1-3); (b) some concerns (4-6); (c) low risk (7-9).

Outcomes and subgroup analyses

Primary outcomes were subsequent hospitalization or emergency department (ED) visit, all-cause mortality. Secondary outcomes were admission to intensive care unit admissions. We conducted a priori determined subgroup analyses to explore the source of heterogeneity among observational studies. We performed stratified analyses by (1) the dose of bamlanivimab (700mg, 2800mg, 7000mg and combination) (2) 14 days or 28 days outcomes.

Statistical Analysis

All statistical analysis was conducted by Stata 16 (StataCorp, College Station, SE) software. Statistical heterogeneity was evaluated by the I-squared (I^2) test. A

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

fixed-effect model was selected if $I^2 < 40\%$. When I^2 value $> 40\%$, heterogeneity was considered significant, and the random-effect model was applied. We used relative risk (RR) for dichotomous data with 95% confidence interval (CI). Publication bias was detected using Egger's test.

Certainty of evidence

The certainty of evidence was rated using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach.

RESULTS

Search results and study characteristics

As shown in Figure. 1, the total search process yielded 460 records. Following removing duplicates publications 243 studies were remained. After screening of titles and abstracts we excluded 156 studies as these include reviews, commentaries, mechanism researches, and irrelevant to COVID-19. After comprehensively screening 77 full texts and assessment of risk of bias, only 10 eligible studies were included, 3 RCTs[11-13] and 7 observational studies[14-20]. We considered observational studies with an NOS score ≥ 6 with high quality. (Figure 1) All studies included were conducted in America. Assessment of bias for the 9 observational studies revealed a moderate risk of bias as assessed against various quality parameters. (Supplementary table 1). 3 RCTs were classified as low risk because they have been clinically registered in USA National Institutes of Health Register (ClinicalTrials.gov) and had registration numbers. (Supplementary table 2). Two RCTs[11, 12] shared one registration numbers (NCT04427501), but the patients were enrolled at totally different time. One RCT[11] has four bamlanivimab arm for the

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

dose. Owing to the different dosage and limited studies, we conducted a subgroup analysis based on the infusion time at 700 mg bamlanivimab.

Outcome of bamlanivimab for COVID-19

Hospitalization or ED visit

Eleven trials (n = 14152 participants) reported on hospitalization or emergency department visit. The use of bamlanivimab compared to placebo could reduce the risk of hospitalizations or emergency department visit (RR 0.41, 95% CI 0.29 to 0.58; I^2= 77.3%, P = 0.000) with low certainty of evidence. (Figure 2) Sensitivity analysis after deleting the study successively revealed the same high heterogeneity.

Mortality

Nine trials (n = 13298 participants) reported on mortality. The use of bamlanivimab compared to placebo could reduce the risk of mortality (RR 0.32, 95% CI 0.13 to 0.77; I^2= 47.5%, P = 0.064 low certain of evidence). (Figure 3) We conducted a sensitivity analysis to investigate the source of the heterogeneity. The study conducted by Lundgren et al. included hospitalized patients and the heterogeneity may be caused by different degrees of severity of the disease in the participant. After excluding that study, the heterogeneity decreased significantly (I^2= 9.4%), and the results showed that the bamlanivimab could significantly decrease the rate of mortality. (RR 0.2 95%CI 0.10 to 0.40)

ICU admission

Only two trials (n = 5073 participants) reported on mortality. The use of bamlanivimab compared to placebo could reduce the risk of ICU admission (RR 0.47, 95% CI 0.23 to 0.92; I^2= 0.0%, P = 0.672 low certainty of evidence). (Figure 4) We did not perform sensitivity analysis.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Safety

In this meta-analysis, 3 RCTs[11-13] reported adverse effects. The pooled result from three trials (n = 1873 participants) found bamlanivimab increased the risk of serious adverse events but no statistic difference. (RR 1.33 95% CI 0.84 to 2.10; I^2 = 0%, P = 0.783 high certainty of evidence) (Figure 5) We did not perform sensitivity analysis about this result.

Subgroup Analysis

Subgroup analysis based on dose

Subgroup analysis showed that the 700mg single bamlanivimab and 2800mg bamlanivimab plus 2800mg etesevimab could reduce the risk of hospitalizations or ED visit compared with the control group. And the combination of two antibodies could reduce more risk than 700mg single antibody (RR:0.29 VS 0.59). Due to only one study in the 2800mg single dose and 7000mg dose, there are no statistic difference between treatment and control group. (Figure 6)

In the part of mortality, there was no significant difference among 7000mg treatment group and control group. Both 700mg and 2800mg bamlanivimab plus 2800mg etesevimab could decrease the mortality (700mg: RR 0.33 95%CI 0.18 to 0.58; I^2 = 0%, P=0.799. 2800mg bamlanivimab plus 2800mg etesevimab: RR 0.05 95%CI 0.00 to 0.81) (Figure 7)

Risk of publication bias

Assessment of publication bias using Egger's test showed that there was significant potential publication bias among the included trials hospitalization or ED visit (p=0.001) and mortality (p=0.006). (Supplementary Figure 1)

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

DISCUSSION

This is the first meta-analysis included 3 RCTs and 9 observational studies investigating the effect of bamlanivimab with or without etesevimab on clinical outcomes. Despite our inclusion criteria that did not specify the severity of the disease, all the studies were conducted with non-hospitalized patients except the RCT by Lundgren 2020 et al[13]. This study provided better evidence for COVID-19 treatment decisions through systematically reviewed, summarized evidence. And our meta-analyses suggested that bamlanivimab may help outpatients to prevent hospitalization, reduce severity and mortality from the disease. What's more, the combination of bamlanivimab and etesevimab could play a bigger role in the outcomes. Last but also important, early treatment is more effective. There is slightly trend on increasing serious adverse events. The certainty of the evidence of the all-cause hospitalization or ED visit and mortality was low. All observational studies adjust the age confounders, but patients in exposed group had higher risk factor for severe COVID-19 than nonexposed group. And there still was a trend toward a lower risk of hospitalization in bamlanivimab treated patients. Most studies' patients we included were at mild or moderate severity COVID-19. Only one RCT[13] , included hospitalized patients whose infusion time was within 12 days of symptom onset, which announced that no clinical benefit of bamlanivimab administration in patients with already present symptoms of COVID-19. Another study[21] showed the contrary results which only treated to hospitalization. But early intervention of this study is rather comparable to the recently outpatient studies.

It has been proposed that bamlanivimab has ability to neutralize the spike protein of SARS-CoV-2 and consequently block attachment to the human angiotensin-converting enzyme 2 (ACE-2) receptor and deny host cell entry. The FDA announced that bamlanvimab has a definite therapeutic effect on COVID-19. However, Lilly, the company that makes bamlanivimab suggested that it would be

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

unlikely to help patients who admitted to hospital with COVID-19. What's more, potential drawbacks of monoclonal antibodies have also become clear, such as immune escape by selection of viral mutations[22]. For instance, E484K-carrying SARS-CoV-2 variants could resistant to bamlanivimab which emergence and expansion of had been at least partially underestimated[23] And bamlanivimab lost its ability to bind to the spike protein and no longer neutralized the Delta variant[24, 25]. Combinations of two or more monoclonal antibodies or polyclonal antisera may therefore increase the barrier sufficiently to prevent escape of the immune system as known from other viral infections[26].

There are some limitations on our meta-analysis. First, groups in some studies were unlikely considered to be comparable on each variable used in the adjustment such as immunosuppression and comorbidity. Second, the small number of participants in some RCTs may increase the likelihood of type II statistical error. Larger scale RCTs are required to confirm the findings. Third, the primary focus of this meta-analyses was cohort studies. Theoretically, observational studies would overestimate the treatment effect of the interventions [27]. Fourth, the data were too limited to perform more meaningful outcome or subgroup analyses. Fifth, the results of egger's test mean there were high risk of selective reporting or of publication bias.

Conclusion

Our study showed that bamlanivimab has might be beneficial for mild or moderate ill patients with COVID-19. Combinations of two or more monoclonal antibody increase the effect. Well-designed clinical trials to identify the clinical and biochemical characteristics in COVID-19 patients' population that could benefit from bamlanivimab are warranted in the future.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Authors' Contributions

Wen-xing Peng, and Huai-rong Xiang designed this study; Xuan Cheng and Bei He ran the searched strategy; Huai-rong Xiang and Yun Li selected articles and extracted data; Qi-zhi Zhang and Yun Li evaluate the quality of the literature. Huai-rong Xiang wrote the manuscript, Xuan Cheng, Yun Li, Bei He and Qi-zhi Zhang edited. All listed authors reviewed and approved the final manuscript.

Competing interests

The authors declared there are no competing interests.

Data availability statement

All data relevant to the study are included in the article or uploaded as supplementary information. The data are available by accessing the published studies listed in table 1.

Acknowledgments

None

Reference

[1] Tyagi K, A Ghosh, D Nair, et al. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes Metab Syndr. 2021;15(3):1007-1008.

[2] Baral PK, J Yin, MNG James. Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. Int J Biol Macromol. 2021;186:490-500.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

[3] Casadevall A, E Dadachova, LA Pirofski. Passive antibody therapy for infectious diseases. #N/A. 2004;2(9):695-703.

[4] Dale AP, MJ Hudson, T Cullen, et al. Administration of Bamlanivimab to Skilled Nursing Facility Residents During a COVID-19 Outbreak, January-February 2021, Arizona. J Am Med Dir Assoc. 2021;22(7):1357-1358.

[5] COVID-19 news release: FDA authorizes monoclonal antibody for treatment of COVID-19. US Food and Drug Administration website. . Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19.

[6] Moher D, A Liberati, J Tetzlaff, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097.

[7] Stroup DF, JA Berlin, SC Morton, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.

[8] McGowan J, M Sampson, DM Salzwedel, et al. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. J Clin Epidemiol. 2016;75:40-46.

[9] Higgins JP, DG Altman, PC Gotzsche, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

[10] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605.

[11] Gottlieb RL, A Nirula, P Chen, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: a Randomized Clinical Trial. JAMA. 2021;325(7):632-644.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

[12] Dougan M, A Nirula, M Azizad, et al. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. New Engl J Med. 2021.

[13] Lundgren JD, B Grund, CE Barkauskas, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. New Engl J Med. 2021;384(10):905-914.

[14] Rainwater-Lovett K, JT Redd, MA Stewart, et al. Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States. Open Forum Infect Dis. 2021;8(8):ofab398.

[15] Ganesh R, CF Pawlowski, JC O'Horo, et al. Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. J Clin Invest. 2021.

[16] Kumar RN, EL Wu, V Stosor, et al. Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2021.

[17] Iqbal L, TJ Terlau, A Hernandez, et al. Efficacy of Bamlanivimab in Reducing Hospitalization and Mortality Rates in COVID-19 Patients in a Rural Community. Cureus. 2021;13(7).

[18] Destache CJ, SJ Aurit, D Schmidt, et al. Bamlanivimab Use in Mild-to-Moderate COVID-19 Disease: A Matched Cohort Design. Pharmacotherapy. 2021.

[19] Bariola JR, EK McCreary, RJ Wadas, et al. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality among Nonhospitalized Adults with Severe Acute Respiratory Syndrome Coronavirus 2 Infection. #N/A. 2021;8(7).

[20] Webb BJ, W Buckel, T Vento, et al. Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. Open Forum Infect Dis. 2021;8(7):ofab331.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

[21] Koehler J, B Ritzer, S Weidlich, et al. Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany. Infection. 2021:1-6.

[22] Schoofs T, F Klein, M Braunschweig, et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science. 2016;352(6288):997-1001.

[23] Tuccori M, I Convertino, S Ferraro, et al. An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opin Drug Discov. 2021:1-12.

[24] Planas D, D Veyer, A Baidaliuk, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276-280.

[25] Connor BA, M Couto-Rodriguez, JE Barrows, et al. Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case. Int J Infect Dis. 2021.

[26] Margolis DM, RA Koup, G Ferrari. HIV antibodies for treatment of HIV infection. Immunol Rev. 2017;275(1):313-323.

[27] Vandenbroucke JP. Why do the results of randomised and observational studies differ? Bmj. 2011;343:d7020.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.




Figure 1: Preferred Reporting Items for Systematic Review and Meta- analysis (PRISMA) flow diagram for the systematic review and meta- analysis.




Figure 2: Forest plot of pooled hospitalization or ED visit rate across all included studies. Weights are from random-effects analysis. Note: CI = Confidence Interval, ED = Emergency Department

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.





Figure 3: Forest plot of pooled mortality rate across all included studies. Weights are from random-effects analysis. Note: CI = Confidence Interval.



medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 4: Forest plot of pooled ICU admission rate across all included studies. Weights are from random-effects analysis. Note: CI = Confidence Interval.




Figure 5: Forest plot of pooled serious adverse events rate across all included studies. Weights are from Fixed-effects analysis. Note: CI = Confidence Interval.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.




Figure 6: Forest plot for subgroup analysis of hospitalization or ED visit rate by type of dose. Weights are from random-effects analysis. Note: CI = Confidence Interval. 2800mg B and 2800 E = 2800mg bamlanivimab plus 2800mg etesevimab

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.




Figure 7: Forest plot for subgroup analysis of mortality rate by type of dose. Weights are from random-effects analysis. Note: CI = Confidence Interval. 2800mg B and 2800 E = 2800mg bamlanivimab plus 2800mg etesevimab

Table 1 Characteristics of the studies included in the meta□analysis

Frist author, year	Type of study	country	Mean age IQR or SD (treatment group)	Enrolled patients	Timing of using bamlanivimab	Dose	Outcome
Dougan 2021	RCT	USA	53.8±16.8	aged 12 years or older with mild or moderate symptoms; with at least one risk factor for severe Covid-19	Positive SARS-CoV-2 test ≤3 days before infusion	a combination of 2800 mg of bamlanivimab and 2800 mg of etesevimab or placebo	1. the overall clinical status of the patients, defined as Covid-19–related hospitalization (acute care for ≥24 hours) or death from any cause by day 29. 2. change from baseline to day 7 in the SARS-CoV-2 viral load. 3. the time to sustained patient-reported resolution of symptoms.
Gottlieb 2020	RCT	USA	44 (30-60)	aged 18 years or older, tested positive for SARS-CoV-2 infection, had 1 or more mild to moderate symptoms.	Positive SARS-CoV-2 test ≤3 days before infusion	placebo, 700,2800 ,7000 mg of bamlanivimab, and a combination treatment with 2800 mg of bamlanivimab and 2800 mg of etesevimab.	1. The change in log viral load from baseline to day 11. 2. time to symptom improvement; time to symptom resolution; and the proportion of patients showing symptom improvement or resolution at days 7, 11, 15, and 22) 3. focused on clinical outcomes (the proportion of patients with a COVID-19–related hospitalization, emergency department visit, or death) at day 29.
Lundgren 2020	RCT	Denmark	63 (50–72)	adult hospitalized patients who had documented SARS-CoV-2	within 12 days of symptom onset	7000mg of bamlanivimab	1. the time to a sustained recovery, which was defined as hospital discharge to home and

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

				infection and a duration of symptoms attributable to Covid-19 of 12 days or less.			remaining at home for at least 14 days 2. death from any cause.
Bariola 2021	observational study	USA	67 .3 (13.0)	diagnosed mild to moderate COVID-19 (with a positive polymerase chain reaction or antigen test for SARS-CoV-2 virus); body mass at least 40 kg; age ≥65 years; or a medical condition conferring high risk of COVID-19 progression to severe disease and/or hospitalization	within 10 days of symptom onset	700mg of bamlanivimab	1. a composite of hospitalization or all-cause mortality during the follow-up windows. 2. hospitalization or 28-day ED visit without hospitalization.
Destache 2021	Cohort study	USA	72 (65-80)	one of the following risk factors: age greater or equal to 65 years, BMI greater than or equal to 35, chronic kidney disease, diabetes, immunosuppressive disease, immunosuppressive treatment, age greater than or equal to 55 years and cardiovascular disease, age greater than or equal to 55 years and hypertension, age greater than or equal to 55 years and chronic respiratory pulmonary disease or other chronic respiratory diseases, or	NA	NA	Subsequent hospitalization or an ED visit

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

				age less than 55 years with sickle cell disease, congenital or acquired heart disease, neurodevelopment disorders, medical related technological device dependence, asthma, or reactive airway disease. Patients identified in this report were then searched to determine if they received BAM treatment as part of their COVID-19 infection treatment.			
Ganesh 2021	Cohort study	USA	63 (52,72)	age ≥65 years, body mass index (BMI) ≥35, diabetes, chronic kidney disease, immunosuppressive medication use, or an immunocompromising condition. Patients 55 years and older qualified if they had hypertension, cardiovascular disease, or chronic lung disease. Mild or moderate	within 10 days of symptom onset	700mg of bamlanivimab	1. All-cause hospitalization 2. Intensive care unit admissions 3. Survival 4. Adverse Events
Kumar 2021	Case-control study	USA	66 (57–74)	Prescribing clinicians attested in the bamlanivimab referral order that the patient (1) was not hospitalized at time of order placement, (2) had no acute need for oxygen therapy or, for	<10 days from initial symptom onset, and <5 days from first positive SARS-CoV-2 test.	single infusion of 700 mg	1. The primary outcome was hospitalization within 30 days from initial positive SARS-CoV-2 PCR. Demographics, comorbidities, and presentation characteristics were compared between cases and controls.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

				those patients on oxygen at baseline, no increase in oxygen requirement, (3) was age 18 years or older, (4) had positive SARS-CoV-2 testing, (5) and whether the patient weighed ≥40 kg.			2. Secondary outcomes included: intensive care unit (ICU) admission, mechanical ventilation requirement, mortality, and duration of hospitalization within 30 days from first positive SARS-CoV-2 test.
Rainwater 2021	Cohort study	USA	63.9 (15.9)	tested positive for SARS-CoV-2 via an antigen or polymerase chain reaction-based test. Patients with positive viral test results recorded in the electronic health record between July 1st and December 20th	with symptom onset within no more than 10 days.	NA	1. medical visit was defined as the first instance of COVID-19-related E.D. visit or hospitalization after positive SARS-CoV-2 viral test result. 2. Adverse Events
Webb 2021	Cohort study	USA	65 (13)	Patients were ineligible to receive MAb therapy for the following conditions: 1) hospitalized due to COVID-19, 2) new, COVID-related hypoxemia (defined as peripheral oxygen saturation <90% at rest or new supplemental oxygen requirement, or for those with chronic hypoxia, a new change in baseline saturation or oxygen demand, 3) pregnant, or 4) known hypersensitivity to other monoclonal drugs. Eligibility criteria for pediatric patients differed from adults and	with symptom onset within no more than 7 days.	700mg of bamlanivimab	The primary outcome was emergency department visit or hospitalization within 14 days of positive test.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

				patients <18 years of age are not included in this study.			

Table 2. Outcome summary


Outcome	Study(n)	RR	95% CI
Hospitalization or ED visit	9	0.41	(0.29, 0.58)
Mortality	8	0.32	(0.13, 0.77)
ICU admission	2	0.47	(0.23, 0.92)
Safety	3	1.33	(0.84, 2.10)

Subgroup	Study (n)	RR	95% CI
Dose	**Hospitalization or ED visit**		
	Mortality		
700mg B	5	0.59	(0.46, 0.76)

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.


	6	0.33	(0.18, 0.58)
2800mg B	1	0.32	(0.07, 1.43)
	0	NA	NA
7000mg B	1	0.33	(0.07, 1.52)
	1	1.67	(0.57, 4.86)
2800mg B+2800mgE	2	0.29	(0.15, 0.54)
	1	0.05	(0.00, 0.81)

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.



(a)

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.



(b)

Figure 1: Risk of publication bias. (a)hospitalization or ED visit; (b)mortality

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 1. Risk of bias summary: the review authors' judgments about each risk-of-bias item for each included cohort study.

Study	Patients' selection	Comparability between groups	Outcome or exposure factors assessment	NOS score	Risk of bias
Bariola 2021	3	2	2	7	L
Destache 2021	4	2	2	8	L
Iqbal 2021	3	2	3	8	L
Ganesh 2021	3	2	3	7	L
Kumar 2021	3	1	2	6	M
Rainwater 2021	3	1	2	6	M
Webb 2021	3	2	1	6	M

NOS: New-Castle Ottawa scale; The summary risk of bias was determined as low (NOS scores≥7), moderate (4≤NOS scores≤6), and high (NOS scores≤3).

L: low risk; M: moderate risk; H: high risk

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table 2: Risk of bias summary: the review authors' judgments about each risk-of-bias item for each included randomized control trial.

Study	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias
Gottlieb et al (2021)	L	L	L	U	L	L	L
Lundgren et al(2021)	L	L	L	L	L	L	L
Dougan et al (2021)	L	U	L	U	L	L	L

L: low risk; U: unclear risk; H: high risk

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table 3: GRADE summary of findings on use of intravenous immunoglobulin in COVID-19

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk Control	Corresponding risk Hospitaliazation or ED visit				
Hospitaliazation OR ED visit	**Study population**		**RR 0.41**	15201	⊕⊕⊝⊝	
Follow-up: 14-30 days	**194 per 1000**	**79 per 1000** (58 to 108)	(0.3 to 0.56)	(9 studies)	**low**[1,2,3,4]	
	Moderate					
	200 per 1000	**82 per 1000** (60 to 112)				
Death rate	**Study population**		**RR 0.31**	14347	⊕⊕⊝⊝	
Follow-up: 14-30 days	**13 per 1000**	**4 per 1000** (2 to 10)	(0.12 to 0.77)	(8 studies)	**low**[1,2,3]	
	Moderate					
	23 per 1000	**7 per 1000** (3 to 18)				
ICU adimision	**Study population**		**RR 0.47**	5073	⊕⊕⊝⊝	
Follow-up: 30	**10 per 1000**	**5 per 1000** (2 to 9)	(0.23 to 0.92)	(2 studies)	**low**	
	Low					

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

	0 per 1000	**0 per 1000** (0 to 0)			
	Moderate				
	18 per 1000	**8 per 1000** (4 to 17)			
Serious advers effects Follow-up: 30 days	**Study population**		**RR 1.33** (0.84 to 2.1)	1814 (3 studies)	⊕⊕⊕⊕ **high**
	33 per 1000	**44 per 1000** (28 to 69)			
	Moderate				
	10 per 1000	**13 per 1000** (8 to 21)			

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; **RR:** Risk ratio;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Very low quality: We are very uncertain about the estimate.

[1]

[2] Significant potential publication bias

[3] RR < 0.5

[4] Dose depend gradient

medRxiv preprint doi: https://doi.org/10.1101/2021.08.24.21262580; this version posted August 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.